Integra LifeSciences Q3 adjusted EPS seen at $0.55-$0.59; revenue seen at $410-$412 million
IART•Integra LifeSciences expects Q3 2026 revenue of $410 million-$412 million and adjusted EPS of $0.55-$0.59. It lowered its 2026 revenue outlook to $1.634 billion-$1.654 billion and adjusted EPS guidance to $2.30-$2.40, citing flooding-related supply disruption.
1. Flooding affects outlook
Integra estimates flooding-related supply disruption reduced Q3 revenue by about $7 million and expects a $15 million-$20 million revenue hit in Q4. It still projects 2026 operating cash flow of about $190 million-$200 million and expects Q3 operating cash flow above $85 million.
2. Manufacturing recovery
The Cincinnati site is expected to return to full manufacturing operations in Q2 2027. Integra expects insurance recoveries to offset a substantial portion of the earnings impact.
